Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Pharma
FDA approves 2nd indication for Amgen, AstraZeneca's Tezspire
The FDA has endorsed Amgen and AstraZeneca’s Tezspire for patients age 12 and older with chronic rhinosinusitis with nasal polyps.
Kevin Dunleavy
Oct 17, 2025 5:12pm
Amgen unveils DTC platform with 60% discount on Repatha
Oct 6, 2025 11:01am
Amgen's Repatha meets the mark in CV primary prevention trial
Oct 2, 2025 11:26am
Amgen lays out $650M to grow Puerto Rico site
Sep 26, 2025 10:40am
Settlement allows Sandoz to launch Eylea biosimilar in late 2026
Sep 9, 2025 10:30am
Novartis-Argo, Eisai, Henlius—Fierce Pharma Asia
Sep 5, 2025 9:00am
